EMEA-002240-PIP02-17-M02
Submitted by Anonymous (not verified) on 14 February 2024 - 15:03
EMEA-002240-PIP02-17-M02
3-year work plan for Biosimilar Medicinal Products Working Party (BMWP) 2024-2026
Submitted by Anonymous (not verified) on 14 February 2024 - 15:02
3-year work plan for Biosimilar Medicinal Products Working Party (BMWP) 2024-2026
3-year work plan for the Biologics Working Party (BWP) 2024-2026
Submitted by Anonymous (not verified) on 14 February 2024 - 14:55
3-year work plan for the Biologics Working Party (BWP) 2024-2026
EMEA-002320-PIP01-17-M03
Submitted by Anonymous (not verified) on 14 February 2024 - 14:37
EMEA-002320-PIP01-17-M03
Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline
Submitted by Anonymous (not verified) on 14 February 2024 - 14:27
Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline
Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro, lanadelumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0037/2023
Submitted by Anonymous (not verified) on 14 February 2024 - 13:34
Opinion/decision on a Paediatric investigation plan (PIP): Takhzyro, lanadelumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0037/2023
EMEA-003212-PIP01-22
Submitted by Anonymous (not verified) on 14 February 2024 - 13:11
EMEA-003212-PIP01-22
EMEA-003207-PIP01-22
Submitted by Anonymous (not verified) on 14 February 2024 - 13:02
EMEA-003207-PIP01-22
EMEA-003177-PIP01-21
Submitted by Anonymous (not verified) on 14 February 2024 - 12:50
EMEA-003177-PIP01-21
EMEA-002283-PIP01-17-M04
Submitted by Anonymous (not verified) on 14 February 2024 - 10:45
EMEA-002283-PIP01-17-M04